J Thromb Haemost: Benzodiazepines and venous thrombosis risk.

Venous thrombosis (VTE) is a life-threatening disease, and some studies have shown that the use of benzodiazepines (BZRA) may increase the risk of VTE, but this association lacks evidence based on population.
recently, a study published in the authoritative journal Journal of Thournal of Thrombosis and Haemostasis explores the link between BZRA use and VTE risk.
From January 1, 2002 to December 31, 2012, researchers analyzed Taiwan's claims database and conducted a nested case-control study of patients with at least one new BZRA prescription, including new user years two years ago without any BZRA prescriptions, and identified cases with VTE and disease risk scores and matching comparors.
researchers used the logistic regression model to explore the association between BZRA exposure and VTE risk, and comprehensively assessed the exposure time, dose, and category of BZRA.
researchers identified 2,800 VTE cases and 2,800 matching controls.
the current BZRA prescription (-90 days) is related to the occurrence of VTE (adjusted ratio ratio of 1.83; 95% CI: 1.62-2.06).
-benzodiazepines (aOR:2.00; 95%CI: 1.45-2.76) VTE risk point estimates are slightly higher than non-benzodiazepines (aOR: 1.39; 95% CI: 1.07-1.81).
use of BZRA, the number of BZRA used, and the use of higher doses of BZRA increase the risk of VTE.
the VTE risk of using fluoroxyazole was higher than that of other BZRA (aOR: 2.99; 95% CI: 1.43-6.28) when evaluating individual BZRAs.
study suggests that current use of BZRA may increase the risk of VTE.
same time, benzodiazepines, especially fluorinated nitroxipam, have a higher risk of VTE.
.